Jan.—DiaDexus (developed a blood test to predict cardiovascular disease and is working on one for breast cancer) has raised $40mm through its Series E venture round. Returning backers Baker Brothers and Scale Venture Partners co-led the financing and were joined by fellow shareholders GlaxoSmithKline, Rho Ventures, Bain Capital's Brookside Fund, and Mosaix Ventures as well as new investor Burrill & Co.
Feb.—Biofusion PLC has spun off a new company, Absynth Biologics Ltd. , which will develop vaccines and antibodies against Staphylococcus...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?